Home > Oncology > Androgen deprivation appears beneficial in unfavorable intermediate-risk PC

Androgen deprivation appears beneficial in unfavorable intermediate-risk PC

Journal
JAMA Network Open
Reuters Health - 11/09/2020 - Androgen-deprivation therapy (ADT) does not improve outcomes in patients with favorable intermediate-risk prostate cancer (PC) undergoing radiation therapy (RT), but it may benefit patients with unfavorable intermediate-risk disease when combined with RT, new research suggests. "Our findings argue strongly against the routine use of androgen deprivation therapy for favorable intermediate-risk prostate cancer patients undergoing radiation therapy," Dr. Zachary S. Zumsteg of Cedars-Sinai Medical Center in Los Angeles told Reuters Health by email. The use of ADT in intermediate-risk PC is controversial, Dr. Zumsteg and his team note in JAMA Network Open. Retrospective studies have shown benefit only in patients with disease stratified as unfavorable. The researchers performed a secondary analysis of the RTOG 9408 randomized controlled trial of RT with or without four months of ADT, including 377 patients with favorable intermediate-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on